Live birth following multimodal therapy in a patient with asherman's syndrome, recurrent pregnancy loss, and polycystic ovarian syndrome: a case report and literature review
Xu Q., Li L., Li B., Tang Z., Ma Y., Tao L.
Prospective Study, published in Contracept Reprod Med (2025) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Contracept Reprod Med (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40770747
- PMCID
- PMC12330053
- DOI
- 10.1186/s40834-025-00384-1
Abstract (original English)
Background Improving the endometrial thickness (EMT) and pregnancy outcomes in cases of thin endometrium (TE) induced by severe intrauterine adhesion (IUA) is a significant clinical challenge. This report provides insight into a potential protocol for improving EMT and pregnancy outcomes in challenging cases of TE induced by IUA, especially for patients with concurrent polycystic ovary syndrome (PCOS) and experiencing recurrent spontaneous abortion (RSA). Case presentation We report the case of a 29-year-old woman with severe IUA, RSA, and PCOS, who experienced three spontaneous abortions. Copy number variations (CNV's) detection of fetal villi from the last abortion indicated Turner syndrome. Hysteroscopic adhesiolysis (HA) had been performed twice previously. She subsequently underwent superovulation using an antagonist regimen, resulting in oocyte retrieval and cryopreservation of four transplantable blastocysts after genetic testing. After three rounds of HA, the uterine cavity shape returned to normal. She then received two cycles of Femoston and/or estradiol valerate therapy combined with oral low-dose aspirin, vaginal sildenafil, pelvic floor electrical stimulation, and uterine perfusion platelet-rich plasma (PRP); however, the frozen embryo transfer (FET) was canceled as the EMT remained 4.9 mm and 3.9 mm. After three additional HA procedures and one hysteroscopy, the u
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.